The answer is yes. A study published in 2017 in the journal Proceedings of the National Academy of Sciences (PNAS) showed that the frequency of osteoarthritis of the knee doubled between the beginning of the 20th century and today, at the same age. This phenomenon is partly explained by the increase in sedentary lifestyle and the change in diet, which is now too rich in fat, which causes overweight and metabolic diseases. Obviously, the aging of the population also means that we have more and more cases of osteoarthritis.
At the moment, there is no drug that can delay or stop osteoarthritis. We can only act on the risk factors: losing weight, doing physical activity. The only drugs available are aimed at reducing pain. These are paracetamol , anti-inflammatory drugs, tramadol and exceptionally strong opioids, but we avoid prescribing them because of their side effects and the dependence they cause . We can also inject cortisone in the event of an outbreak of osteoarthritis. Finally, you can inject hyaluronic acid, but this is no longer reimbursed by Health Insurance.
There are several avenues of research: biotherapy to stimulate cartilage growth (there is an international trial underway), biotherapy against osteoarthritis pain (studies are underway to ensure its tolerance. The objective market is set for late 2019, early 2020) as well as drugs targeting enzymes that degrade cartilage. We also hope to develop drugs capable of eliminating these senescent cells responsible for inflammation of the joints.
There is also an international trial underway that aims to regrow cartilage by injecting a growth factor into the joint. Regarding pain, there is a molecule that has demonstrated its effectiveness. Studies are underway to ensure its tolerance. The target for marketing is set for late 2019, early 2020. And then there is also a major European project, the ADIPOA trial, where stem cells are taken from the belly fat to inject them into the knee. . Stem cells are able to make anti-inflammatory molecules that could delay the progression of the disease. Three French hospitals are participating and the results are expected by the end of 2019.
Yes, and we know that investing in research on rheumatism leads to remarkable solutions as proved by the effectiveness of biotherapies in rheumatoid arthritis or spondyloarthritis. But for this research to continue, we must continue to invest! However, it should be emphasized that we can act now by acting on our lifestyle, even before thinking about taking medication. We are born with a determined bone and joint capital that we gradually lose. The goal is to keep it as long as possible thanks to these preventive measures.